Preparations in capsules, e.g. of gelatin, of chocolate (A61K9/48)

Pharmacological composition on basis of iron compounds // 2625739
FIELD: pharmacology.SUBSTANCE: invention is a pharmacological composition containing the iron (II) sulphate for treatment of iron deficiency anemia, characterised in that it additionally contains iron hexacyanoferrate, iron-potassium hexacyanoferrate, potassium sulfate and micro cellulose, the components in the composition being in a certain ratio, in weight percent.EFFECT: high therapeutic efficacy, good tolerability, and low toxicity.2 cl, 5 ex
Pharmaceutical antidiabetic composition based on (+)-cis-3-(1h-benzimidazol-2-yl)-1,2,2-trimethylcyclopentane carboxylic acid // 2624872
FIELD: pharmacology.SUBSTANCE: invention relates to a pharmaceutical antidiabetic composition based on (+)-cis-3-(1H-benzimidazol-2-yl)-1,2,2-trimethylcyclopentane carboxylic acid, characterized in that it comprises microcrystalline cellulose 102, Povidone K30, croscarmellose sodium, magnesium stearate and talc as pharmaceutically acceptable excipients.EFFECT: increased bioavailability of the formulation active agent.2 cl, 3 dwg, 4 ex
ethod of obtaining a block copolymer // 2623426
FIELD: chemistry.SUBSTANCE: block copolymer has the following formula (1): ,where R1 is a hydrogen atom or a (C1-C5) alkyl group; R2 is a (C1-C5) alkylene group; R3 is a methylene or ethylene group; R4 represents a hydrogen atom or a (C1-C4) acyl group; R5 is a hydroxyl group, an aryl (C1-C8) alkoxy group which may have a substituent, or -N (R6) -CO-NHR7, where R6 and R7 may be the same or different and each represents a cyclic (C3-C6) An alkyl group or a (C1-C5) alkyl group which may be substituted with a tertiary amino group; N is 20-500; M is 2-200; But is 0-100; B is 0-100, provided that the sum of a and b is greater than or equal to 1 and not more than m; The fraction of the R5 group representing the hydroxyl group is 0-5% of m; proportion of the R5 group representing an aryl (C1-C8) alkoxy group which may have a substituent is 10-80% of m; The fraction of the R5 group representing -N (R6) -CO-NHR7 is 11-30% of m. The process for preparing the block copolymer is that the compound of the formula (2) is reacted, wherein R1, R2, R3, R4, n are as defined above; x is 0-100, y is 0-100, the sum of x and y is 2-200, with aryl (C1-C8) alkyl alcohol, and a carbodiimide-based compound in an amount of 2(x+y) equivalents or more relative to the amount of carboxyl Groups in the compound of formula (2). The reaction is carried out in a solvent at a temperature of 15-30°C for 2-48 hours.EFFECT: invention allows to maintain the process in a single reactor, reduce manufacturing period and reduce the quantity of solvent.4 cl, 1 tbl, 6 ex
Agent with isoniazid-containing liposomes // 2622755
FIELD: pharmacology.SUBSTANCE: capsules for oral use comprise liposomes prepared by mixing egg lecithin, PEG 2000 and Tween-80 at the ratio of 6:2:1 at a temperature of 40°C, followed by hydration, encapsulated for oral use, wherein liposomes comprise isoniazid as an active agent in the following ratio of liposome components, g per 1 capsule: isoniazid - 0.3; a mixture of phospholipid, PEG 2000 and Tween-80 - 0.22. Number 0 capsules with a diameter of 7.65 mm, length of 21.7 mm, filling volume of 0.68 ml are additionally used.EFFECT: agent has antiphthisic effect, as well as constant-rate release of active agents and pronounced prolonged action, it is convenient for using by patients themselves.3 tbl, 3 ex
Pharmaceutical composition for sleep disorders prevention and treatment // 2620855
FIELD: pharmacology.SUBSTANCE: invention relates to a pharmaceutical composition for sleep initiating and maintaining and prophylaxis of animal and human states that are accompanied by sleep disorders of a different nature, including a combination of active agents consisting of 0.5-45 mg of doxylamine succinate and long-acting melatonin in amount of 0.1-20 mg.EFFECT: synergistic therapeutic effect and reduced side effects.2 cl, 1 tbl, 5 ex
Pharmaceutical compositions comprising camptothecin derivative // 2620331
FIELD: pharmacology.SUBSTANCE: composition comprising 7-tret-butoxyiminomethyl camptothecin, as an active agent, and a carrier comprising a lipophilic component, a surfactant, a hydrophilic component and a co-solvent. The lipophilic component is a propylene glycol monoester of caprylic acid. The surfactant is vitamin E TPGS. The hydrophilic component is PEG 400. The co-solvent is ethanol. Also, a method for composition preparation and a method of treatment are disclosed.EFFECT: increased bioavailability of 7-tret-butoxyiminomethyl camptothecin.5 cl, 6 ex
Capsules for complex treatment of urinary system diseases // 2619736
FIELD: medicine, pharmacy.SUBSTANCE: invention refers to medicine, namely to pharmacy, and concerns the development of tools for complex treatment of urinary system diseases. The means has the form of microgranules, enclosed in a gelatin capsule. The means comprises mebeverine hydrochloride, cowberry extract, cranberry extract, as active ingredients, potato starch and glucose, as well as hydroxyethylcellulose, applied in the form of 0.25% aqueous solution as granulation liquid for microgranules preparation, as auxiliary substances.EFFECT: invention provides improved therapeutic effect and bioavailability of capsules.2 cl, 3 tbl, 3 ex
Pharmaceutical compositions comprising aromatase inhibitor // 2617510
FIELD: medicine, pharmacy.SUBSTANCE: this invention refers to low-dose pharmaceutical compositions comprising an aromatase inhibitor 4.4-'[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitril as an active ingredient in a suitable carrier. Furthermore, this invention refers to the process for their preparation and application as medicaments.EFFECT: invention expands the range of low-dose pharmaceutical compositions comprising the aromatase inhibitor.11 cl, 4 ex, 4 tbl

Vegetable combined cryo-powder based preparations // 2617434
FIELD: pharmacy.SUBSTANCE: vegetable combined preparation with diuretic, and/or antibacterial, and/or litholytic action containing common agrimony grass and dog rose root cryo-powders and auxiliaries.EFFECT: preparation has an effective diuretic, or antibacterial or litholytic action.7 cl, 12 dwg, 11 tbl

Pharmaceutical composition containing olmesartan medoxomil and rosuvastatin or its salt // 2616516
FIELD: pharmacy.SUBSTANCE: invention provides a pharmaceutical composition which is a single-dose dosage form comprising a compartment containing olmesartan medoxomil and a compartment comprising rosuvastatin or its salt, wherein the said compartments are formed in the isolated form. The compartment containing olmesartan medoxomil comprises from 7.5 to 65 wt % of hydroxypropylcellulose with a low degree of substitution. The compartment comprising rosuvastatin or its salt includes one or more disintegrants selected from the group consisting of crospovidone, hydroxypropyl cellulose with a low degree of substitution, croscarmellose sodium and carboxymethylcellulose calcium. The disintegrant in the said compartment with rosuvastatin is present in the amount of from 2 to 20 wt %. The pharmaceutical composition is a bilayer tablet or a capsule containing granules. The pharmaceutical composition of the present invention solves the problem of slowing down the absorption associated with drug-drug interactions.EFFECT: combination drug of the present invention is bioequivalent to mono-preparation of each of the said drugs.6 cl, 6 dwg, 16 tbl, 9 ex
Solid drug form of indinavir with immediate release and method of obtaining thereof // 2616267
FIELD: pharmacology.SUBSTANCE: group of inventions relates to a solid form of indinavir sulfate, which is a capsule containing 67-79 wt % of indinavir sulfate, 10-20 wt % of lactose monohydrate, 7.7-15 wt % of Prosolv, 0.5-3 wt % of sodium croscarmellose (primellose) 0.5-1 wt % of stearic acid and/or its salt; and a method for its production, according to which indinavir sulfate, lactose monohydrate, croscarmellose sodium and Prosolv are mixed, dusted with stearic acid and/or its salt, encapsulated with simultaneous capsules dedusting and polishing.EFFECT: prompt active agent release and reduced timing of therapeutic effect.5 cl, 3 tbl

Compositions and methods for myelofibrosis treatment // 2616262
FIELD: medicine, pharmacy.SUBSTANCE: capsule containing a mixture of a compound which is N-tert-butyl-3-[(5-methyl-2-{[4- (2-pyrrolidin-1-lethoxi)phenyl]amino} pyrimidin-4-yl)amino]benzenesulphonamide, or a pharmaceutically acceptable salt or hydrate thereof, microcrystalline cellulose and sodium stearyl fumarate. The mixture contains from 10 to 500 mg of the said compound. The weight ratio of the compound to microcrystalline cellulose in the mixture is within the range from 1:1.5 to 1:15. The amount of sodium stearyl fumarate in the mixture is 1% by weight of the capsule contents. A method of capsulesproduction, a method for myelofibrosis treatment and a kit for myelofibrosis treatment are also described. N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl] amino} pyrimidin-4-yl)amino]benzenesulphonamide medication provided as a capsule shows stability and instant release characteristics.EFFECT: invention describes a capsule for oral administration for treatment of myelofibrosis.38 cl, 18 dwg, 25 tbl, 6 ex
Compositions for local use containing diamineoxydase, for treatment or prevention of diseases associated with high levels of histamine, accompanied by increased pain // 2616248
FIELD: medicine, pharmacy.SUBSTANCE: invention refers to pharmaceutical industry and represents application of diamineoxydase to produce a pharmaceutical composition for treatment of diseases or pathologic conditions selected from the group consisting of migraine, fibromyalgia, spondylitis, and muscle contractures, characterized by local application of the composition.EFFECT: invention provides expansion of the arsenal for migraine, fibromyalgia, spondylitis and muscular contractures treatment.12 cl, 6 tbl, 7 ex
Pharmaceutical enteric coated compositions based on mycophenolic acid salt // 2615397
FIELD: pharmacology.SUBSTANCE: group of inventions discloses a pharmaceutical composition comprising of a mycophenolate salt covered with an enteric coating which provides the release of mycophenolate in the upper part of the intestinal tract, and a method of immunosuppression in a patient involving the administration of a therapeutically effective amount of said composition to a patient in need of such therapy.EFFECT: increased efficiency of the composition.15 cl, 2 ex, 1 tbl

Pharmaceutical composition for oral administration containing statin // 2614728
FIELD: pharmaceutics.SUBSTANCE: invention relates to pharmaceutical composition for oral administration containing or consisting of: (i) from 11 to 25 wt% of simvastatin, (ii) from 0.01 to 3 % by weight of first substance (A1) with antioxidant activity, which is butylhydroxyanisole, (iii) from 0.01 to 3 % by weight of second substance (A2) with antioxidant activity, differing from first substance (A1) with antioxidant activity, which is citric acid, and (iv) from 75 to 85 wt% of at least one additive selected from group consisting of filler, binder, agents for controlling fluidity, baking powder and agent preventing adhesion or combinations thereof, where quantitative ratio of butylhydroxyanisole (A1) and citric acid (A2) ranges from 1:95 to 1:30, and wherein above composition is compacted in form of tablet and said tablet has mass from 130 to 300 mg.EFFECT: invention also relates to use of said pharmaceutical composition in medicine.12 cl, 2 ex, 4 tbl, 5 dwg

Stable pharmaceutical composition for oral administration comprising levocetirizine, or pharmaceutically acceptable salt thereof and montelukast or pharmaceutically acceptable salt thereof // 2614382
FIELD: medicine, pharmacy.SUBSTANCE: this present invention relfers to a pharmaceutical composition in the form of a capsule for oral administration for asthma or allergic rhinitis prevention or treatment. The composition comprises: (a) the first fraction of particles in the form of mini-pill comprising levocetirizine, or pharmaceutically acceptable salt thereof and organic acid; and (b) the second fraction of particles in the form of mini-pill comprising montelukast or pharmaceutically acceptable salt thereof. The organic acid is citric acid, tartaric acid, succinic acid or ascorbic acid. The organic acid is present in the amount of 100 parts by weight per 100 parts of levocetirizine. The said first and second particle fractions are physically separated and filled into the capsule. A method for pharmaceutical capsule composition production is also described. The pharmaceutical composition of this invention inhibits the production of related contaminants of levocetirizine and montelukast and provides good stability.EFFECT: invention expands the product range of drugs for allergic rhinitis or asthma prevention or treatment.9 cl, 3 dwg, 4 tbl, 6 ex
Gelatine capsule of selective vessel destruction in tumours // 2613146
FIELD: medicine.SUBSTANCE: gelatine capsule of selective vessel destruction in tumours relates to field of pharmaceutics and medicine, in particular to oncology, and deals with novel medications, mechanism of action of which consists in their destruction of already existing vessels inside tumour, preventing in such way supply of blood and oxygen, vital for survival of solid tumours with dimensions exceeding 1 mm. The capsule contains approximately 250-900 mg of pharmaceutical composition, which contains anti-tumour compound 7-methoxy-4-nitro-3-(p-methoxyphenyl)isoquinolinone 16-18 wt %, crospovidone 5-8 wt %, hypromellose 2-3 wt %, polysorbate 80 - 1-2 wt %, sodium laurylsulphate 0.7-1.2 wt %, the remaining part - mannitol, in gelatine capsule.EFFECT: invention solves the task of creating novel peroral anti-tumour medication for prevention or treatment of benign or malignant tumours, independently on their origin or size, within the framework of treating mammals, in particular humans, resistant to traditional treatment.3 cl, 1 tbl
Pharmaceutical compositions with prolonged release for treating cerebrovascular disorders // 2611339
FIELD: pharmaceutics.SUBSTANCE: invention relates to pharmaceutics. Described pharmaceutical composition of prolonged release for treating of cerebrovascular disorders. Above composition is made in the form of solid gelatine capsules and/or tablets. As an active substance contains 1-hydroxy-4-adamantanone. As an excipients are used fillers, prolonging polymers, sliding substance in amount of (wt%): 1-hydroxy-4-adamantanone – 5.0–50.0; filler – 2.0–92.5; prolonging polymer – 2.0–55.5; lubricant – 0.5–15.0.EFFECT: invention provides increasing of efficiency of using said active substance.4 cl, 23 ex, 6 tbl, 2 dwg
Drug based on tetrametiltetraazobitsiklooktandion and method for its production // 2611194
FIELD: pharmacy.SUBSTANCE: here is a description of dosage form of tetrametiltetraazobitsiklooktandion, additionally containing a filler, granulating agent, lubricant, disintegrant, flavoring agent in certain weight ratios. Methods of preparing of the said dosage form are also described.EFFECT: preparation of the dosage form without defects in manufacture and storage and with improved taste characteristics.11 cl, 3 tbl

Encapsulated dosage form, containing montelukast and levocetirizine // 2606857
FIELD: pharmaceutics.SUBSTANCE: invention relates to capsule dosage form for preventing or treating allergic rhinitis and asthma, which consists of two separate layers: (1) montelukast layer, containing montelukast or its pharmaceutically acceptable salt; and (2) levocetirizine layer, containing levocetirizine or its pharmaceutically acceptable salt, in which said montelukast layer and levocetirizine layer contain water in amount of 5 % and less; and their production method.EFFECT: encapsulated dosage form, according to invention, can completely separate two active ingredients, minimizing so reaction activity between them and improving stability of product with respect to ageing effect and thus optimizing therapeutic action.20 cl, 5 tbl, 9 ex

Pharmaceutical composition having immunostimulating action // 2605832
FIELD: medicine.SUBSTANCE: invention relates to medicine and pharmacy, more specifically to a pharmaceutical composition, having immunostimulating action. Pharmaceutical composition contains N-{2-[3,4-bis-(4-nitrobenzoyloxy)phenyl]ethyl}-4-nitrobenzamine(fentral) as an active substance. Target additives used can be optionally simultaneously corn starch, hydroxypropyl cellulose, microcrystalline cellulose, calcium dihydrophosphate, polyvinyl pyrrolidone, sodium croscarmellose, lactose, sodium benzoate, magnesium stearate, calcium stearate, sorbitol, mannitol. Pharmaceutical composition can be made in form of tablets or capsules. Tablets and capsules with fentral meet State Pharmacopoeia requirements.EFFECT: medicinal agent with fentral has immunostimulating action.1 cl, 6 tbl, 6 ex

Bolus calcium-intensive plus // 2603482
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to veterinary science, and aims at preventing postpartum hypocalcemia in cows. Bolus for preventing postpartum hypocalcemia in cows contains calcium lactate, lactose, sodium bicarbonate, dried spiny eleutherococcus roots. Components are used in claimed amounts.EFFECT: use of invention provides high and prolonged effect in preventing postpartum hypocalcemia in cows.1 cl, 1 tbl

Pharmaceutical composition of n-(6-phenylhexanoyl)glycyl-l-tryptophan amide in solid dosage form // 2602742
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to pharmacy, and concerns pharmaceutical composition in solid dosage form and containing therapeutically effective amount of N-(6-phenylhexanoyl)glycyl-L-tryptophan amide as medicinal substance, and auxiliary substances, which are binding agent of group of substances providing sufficient weight of tablet or capsule: cellulose or cellulose derivatives, such as microcrystalline cellulose; lactose, polyvinylpyrrolidone, calcium carbonate, calcium phosphate; auxiliary substances with high sorption capacity: colloidal silica, magnesium aluminometasilicate; group of sliding agents - stearic acid and/or its salts, surfactants: sodium oleate, sodium lauryl sulphate; disintegrants from group: starch, pectin, polyvinyl pyrrolidone, sodium croscarmellose, sodium carboxymethyl cellulose.EFFECT: tablets and capsules meet all requirements of State Pharmacopeia XI and XII edition and have high bioavailability of above therapeutic peptide.1 cl, 3 dwg, 2 tbl, 16 ex

ethod of producing diclofenac capsules // 2602681
FIELD: pharmaceutics.SUBSTANCE: method of producing diclofenac capsules. Mixture of diclofenac and polyethylene glycol with molecular weight 2,000±400 at weight ratio 1:1-1.5 is dissolved in ethanol at weight ratio of mixture and ethanol 1:0.3-0.6 at temperature of 80±5 °C. Obtained solution at weight ratio of 1:1.75-2 is used for granulation of excipients' mixture: kollidone 90F, polyplasdone XL, starch-1500, lactose, microcrystalline cellulose-101, taken at weight ratio (1:1.9-2.0; 4.6-11.7; 11.7-12.0; 36.0-36.1). Magnesium stearate is added to obtained granulate in amount of 0.5-1.5 % and aerosil of grade 300 is also added in an amount of 2.5-7.5 % of granulate weight. Granulate is dosed in solid gelatinous acid-resistant capsules.EFFECT: method of producing capsules according to the invention allows to improve bioavailability of non-salt form of diclofenac.1 cl, 3 tbl

ethod of producing a pharmaceutical erythromycin composition // 2600924
FIELD: medicine.SUBSTANCE: invention relates to medicine and chemical-pharmaceutical industry and a method of producing a new pharmaceutical erythromycin composition in the form of capsules for use as a broad-spectrum antibiotic. Method of producing a pharmaceutical composition for treating bacterial and protozoal infectious diseases in the form of enterosoluble erythromycin-based capsules comprises mixing erythromycin base or its pharmaceutically acceptable salt with pluronic at a ratio of 70:30, micronization of produced mixture, addition of auxiliary substances, repeated micronization and filling gelatine capsules with the produced mixture. Kolliphor P 188, Kolliphor P 407 or their mixture are used as a pluronic.EFFECT: method is high-tech, and the produced composition and dosage form have high bioavailability of about 70 %, sufficient for considerable reduction of preparation dose (up to 2 g a day) and maintaining a stable erythromycin concentration in blood.6 cl, 3 ex, 2 tbl

ethod of producing extract of castoreum for production of biologically active additives (versions) // 2598706
FIELD: pharmaceutics.SUBSTANCE: invention refers to pharmaceutical industry, namely to a method of producing an extract of castoreum and biologically active additive of it. Method of producing an extract of castoreum for production of biologically active food additive with bracing, tonic, immunomodulatory action, involving bucking of pre-dried castoreum up to homogeneous fine powder, then powder is extracted with water solution of ethyl alcohol, mixture is maintained without access of light, extract is separated by filtration, extraction is carried out at least 3 times, at that, the last extraction is carried out using ultrasound, then extracts obtained after each filtration, are mixed and boiled out under certain conditions. Biologically active additive (BAA) to food - in the form of a tablet. Biologically active food additive - in the form of capsules.EFFECT: method described above allows to produce BAAs, having bracing, tonic and immune modulating properties.3 cl, 1 tbl, 3 ex

Combined delivery system with immediate/sustained release of medicinal agents with short period of half-life, including for remogliflozin // 2596787
FIELD: medicine.SUBSTANCE: disclosed is a combination immediate/delayed release delivery system for compounds which have short half-life, such as antidiabetic remogliflozin etabonate, which provides a dosage form that has two distinct phases of release. Solid phase for immediate release includes remogliflozin etabonate and immediate release material. Solid phase of delayed release comprises remogliflozin etabonate and sustained release material. Solid phase of delayed release has shape of discrete single particles or granules and solid phase for immediate release is a matrix, which consists of separate particles of solid phase of delayed release enclosed in said matrix or dispersed therein. What is also presented is a method for producing a pharmaceutical composition.EFFECT: invention provides a procedure for administering remogliflozina etabonate once a day.9 cl, 4 dwg, 4 tbl, 2 ex
ethod of producing stable soft gel capsule containing micro-encapsulated probiotic bacteria // 2593788
FIELD: medicine. SUBSTANCE: group of inventions relates to production of soft gel capsule containing micro-encapsulated probiotic bacteria, envisaging following steps: (a) providing microencapsulated probiotic bacteria with at least one coating containing at least one vegetable lipid, having a melting point from 35 °C to 75 °C; (b) suspending said microencapsulated probiotic bacteria in suspending preparation to produce filler; (c) mixing said aggregate with intensity less than approximately 3,000 rpm and temperature of approximately 15-32 °C to produce mixed filler; (d) reduction of agglomerates microencapsulated probiotic bacteria in mixed filler to produce deagglomerated filler; and (e) encapsulation deagglomerated aggregate in soft gel capsule, where is maintained integrity coating microencapsulated probiotic bacteria, as well as probiotic soft gel capsule, made in compliance with this method. EFFECT: invention provides higher viability and stability of probiotic bacteria in soft gel capsule at prolonged storage during at least 24 months at room temperature. 18 cl, 4 ex, 10 tbl

Encapsulated preparation for treating cold and method for production thereof // 2590978
FIELD: chemistry.SUBSTANCE: invention relates to chemical-pharmaceutical industry and concerns anticatarrhal preparation in form of capsules filled with micro tablets, and method for preparing it. Method of producing includes mixing of paracetamol, amantadine hydrochloride, caffeine, Bovis calculus artifactus, Chlorpheniramine maleate for 10-15 minutes, powder mixture is passed through sieve with size of 80 mesh and then once more mixed for 10-15 minutes, obtained mixture is sprayed with paste-like mass of hypromellose, prepared by adding purified water to hypromellose at 80 °C, stirring till homogeneous state and holding for 20-25 minutes, coated with hypromellose micro tablets are passed through sieves with size of 14-18 mesh, dried for 55-65 minutes at 40-50 °C and polished with subsequent filling of capsules with mixture of obtained micro tablets.EFFECT: invention provides minimisation of auxiliary substances, simplified production steps (there is no need in separate micronising and pelitizing of each component), high stability of active substances during storage, reduced side effects as dry mucous and sleepiness.2 cl, 4 ex, 3 tbl

Solid dosage form of preparation of sedative and hypnotic effect // 2589833
FIELD: medicine.SUBSTANCE: invention relates to a solid dosage form of sedative and hypnotic effect. Said dosage form is a tablet or capsule, which contains hydroxyzine in amount of 3.33 to 4.5 wt%, ethyl ether of α-bromo-isovaleric acid in amount of 5.47 to 7 wt%, peppermint oil or mixture thereof with hop oil in amount from 0.39 to 0.48 wt%, β-cyclodextrin in amount of 37-50 wt% and additives, including combined water.EFFECT: invention is characterised by high sedative properties and hypnotic efficiency compared to existing analogues, which provides long sleep duration and faster onset thereof.3 cl, 3 tbl, 3 ex

etabiotic composition to ensure colonisation resistance of human intestinal microbiocenosis // 2589818
FIELD: medicine.SUBSTANCE: invention can be used for production of meta-biotic composition to ensure colonisation resistance of human intestinal micro-biocenosis. Meta-biotic component is a rational combination of metabolites of probiotic strains of microorganisms and additionally includes sterilised dried culture liquids containing metabolites of Enterococcus faecium L-3, Lactobacillus delbrueckii TS1-06 and Lactobacillus fermentum TS3-06. Prebiotic component is represented by oat flakes. Composition is presented in a solid dosage form in the shape of capsules, and the number of ingredients in one capsule constitutes, MP: sterilised dried culture liquid containing metabolites of a probiotic strain of bacteria Bacillus subtilis VKPM No. B-2335 - 1.9; the sterilised dried culture liquid containing metabolites of probiotic strain of bacteria Enterococcus faecium L-3 - 4.5; the sterilised dried culture liquid containing metabolites of probiotic strain of bacteria Lactobacillus delbrueckii TS1-06 - 4.5; the sterilised dried culture liquid containing metabolites of probiotic bacterial strain Lactobacillus fermentum TS3-06 - 4.5; zeolite - 64.3; oat flakes - 20.0; calcium stearate or aerosil - 0.3.EFFECT: use of this composition allows to normalise microbiocenosis of the intestine due to selective stimulation of growth and reproduction of Lactobacilli and bifidus bacteria of indigent component of normoflora of a biotope providing specific antagonistic activity with respect to a wide range of pathogenic and opportunistic microorganisms.1 cl, 4 dwg, 19 tbl

Agent with liposomes containing glutamic acid and propolis extract, exhibiting nootropic activity // 2589280
FIELD: pharmaceutics.SUBSTANCE: invention relates to pharmaceutical industry, specifically to an agent possessing nootropic activity. Agent possessing nootropic activity contains glutamic acid, 10 % alcohol extract of propolis, polyethylene glycol (PEG), active substances are included into liposomes, obtained by mixing egg lecithin and PEG 2000, and hydration, then liposomes are enclosed in capsules for oral administration.EFFECT: agent described above possesses pronounced nootropic action.3 cl, 6 tbl, 4 ex
ethod of producing pharmaceutical composition ademetionine and dosage form thereof // 2587331
FIELD: pharmaceuticals; chemistry.SUBSTANCE: invention relates to chemical-pharmaceutical industry, specifically to a method of producing enterosoluble capsules based on S-ademetionine, involving mixing S-ademetionine of 1,4-butanedisulphonate with copolymer of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol with molecular weight 90,000-140,000 g/mol at a ratio of 30:70, micronising produced mixture, addition of auxiliary substances, such as microcrystalline cellulose, aerosil and stearic acid and/or calcium or magnesium salt, repeating micronisation and filling gelatin capsules with obtained mixture at following ratio of components, g/capsule: S-ademetionine of 1,4-butanedisulphonate - 0.100; copolymer of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol with molecular weight 90,000-140,000 g/mol - 0.234; microcrystalline cellulose - 0.221; aerosil - 0.0041; stearic acid and/or calcium or magnesium salt - 0.004.EFFECT: invention provides higher bioavailability of peroral dosage form of ademetionine and possibility to use low therapeutic doses, its controlled release and high therapeutic effect obtained at same time.3 cl, 1 ex

Solid dosage form of procarbazine of immediate release and preparation method thereof // 2586290
FIELD: pharmaceutics.SUBSTANCE: disclosed is a method for preparing solid procarbazine dosage form, in which at temperature of 40-45 °C mannitol, procarbazine hydrochloride and magnesium stearate are mixed, and moistened with starched aqueous solution. Granulates are dried for 10-15 minutes, powdered with mixture of maize starch and talc and encapsulated.EFFECT: disclosed is method for preparing of procarbazine solid dosage form, having anti-tumour activity.1 cl, 2 tbl

Agent with liposomes containing nicotinic acid and propolis extract having detoxification and antioxidant activity // 2585099
FIELD: chemistry.SUBSTANCE: invention relates to an agent possessing detoxification and antioxidant activity. Agent contains nicotinic acid and 10% alcohol extract of propolis, included in liposomes. Said liposomes are obtained by mixing at 40°C egg lecithin and cholesterol, taken in ratio 1:0.2, followed by hydrating with solution of sucrose. Liposomes are enclosed in capsules for oral administration in following ratio of components of liposomes per 1 capsule: 0.2 g nicotinic acid, 0.2 g of 10 % alcohol extract of propolis, 0.22 g of mixture of lecithin and cholesterol 1:0.2, hydrated with 0.5 % sucrose solution.EFFECT: invention is characterised by high bioavailability and marked prolonged action, providing maximum delivery of active substances of gastrointestinal tract in blood flow.3 cl, 5 tbl, 7 ex
edicinal dosage form, which contains 6'-fluor-(n-methyl-or n,n-dimethyl)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indole]-4-amine // 2582390
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to a medicinal dosage form administered two times a day, one time a day or less often, which contains 6'-fluor-(N-methyl- or N,N-dimethyl)-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indole]-4-amine or its pharmaceutically acceptable salt and which releases in vitro at least 50 wt % of a pharmacologically active agent in accordance with European Pharmacopoeia in 900 ml of artificial gastric juice at pH 1.2 and 37±0.5°C 30 minutes later in accordance with the method, with the use of a blade mixer with sinker at 100 rpm; a solid polymeric matrix material specified in a group consisting of polyvinyl pyrrolidone, poly((N-vinylpyrrolidone)-block-poly(vinyl acetate)), and any combinations thereof, wherein the pharmacologically active agent according to general formula (I) is dispersed, and a surfactant having max. HLB of 24; the polymer/pharmacologically active agent ratio falls within the range from 10:1 to 25:1.EFFECT: invention provides creating the dosage form with good bioavailability and storage stability, which also enables the pharmaceutically active agent to inflow quickly into plasma at the start, and relief the patient's pain quickly due to rapid release, and at the same time to ensure the long-lasting therapeutic effect over a relatively long period (at least 12 hours).10 cl, 4 ex, 6 dwg
Pharmaceutical composition of medicinal agent of sedative and spasmolytic action in form of soft gelatine capsules (versions) // 2580290
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions refers to medicine. What is described is a pharmaceutical composition of a medicinal agent of sedative and spasmolytic action in the form of soft gelatine capsules, containing alpha-bromoisovaleric acid ethyl ester and menthol solution in menthyl isovalerate in the following ratio, wt %: alpha-bromoisovaleric acid ethyl ester 2.0-6.0; menthol solution in menthyl isovalerate 31.0-81.2; addition agents - the rest. The addition agent is a substance specified among: fatty component, glycine, taurine, fatty component with glycine, fatty component with taurine, fatty component with glycine and taurine, whereas the fatty component is peppermint oil, olive oil, hop oil, corn oil or any combination of the above substances.EFFECT: providing the combined pharmacological sedative, spasmolytic, depressant, vasorelaxant and analgesic action, improving cardiological action of the agent, achieving high dosage accuracy of the active substances and fast release thereof when in use.2 cl, 11 ex

ethod of obtaining a solid form of the drug sedative and antispasmodic action // 2578432
FIELD: pharmaceuticals.SUBSTANCE: invention relates to the pharmaceutical industry, namely to a process for preparing a solid form of the drug sedative and antispasmodic action by creating a complex of beta-cyclodextrin with a mixture of ethyl ether of alpha-bromine-isovalerianic acid and peppermint oil (EBR-oil mixture).EFFECT: drug obtained by the inventive process is stable.4 cl, 2 tbl, 11 ex
ethod of producing capsules of fingolimod hydrochloride // 2577230
FIELD: chemistry.SUBSTANCE: invention relates to chemical-pharmaceutical industry and represents a method of producing a pharmaceutical composition in the form of capsules, consisting in the fact that is preliminarily sieved substance fingolimod hydrochloride, microcrystalline cellulose, carboxymethyl sodium and calcium stearate or magnesium stearate, mixed in weight ratio of 1:(210-215):(5-7):(1.5-2.5), respectively, to a homogeneous state and dosed mixture in the capsule.EFFECT: invention provides higher accuracy of metering in production of capsules, stable during storage of the product.3 cl, 1 ex

Formulations of vitamin d 14-epi-analogues // 2575792
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmaceutics and concerns a formulation of a soft gelatine capsule containing inecalcitol, at least one long-chain triglyceride (LCT) and pharmaceutically acceptable excipients.EFFECT: invention provides a therapeutic formulation having the improved absorption profile.11 cl, 4 dwg, 2 ex

Device and assembly for connection of at least two medicinal capsules by adhesive joint // 2574955
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions refers to pharmaceutics and is applicable to produce a solid galenic form of a preparation for oral administration. A device (1) for connection of a medicinal capsules (A, B) by an adhesive joint comprises a matrix (10), which limits a capsule (A, B) packing cavity (15) and a space (16); the cavity and space are separated from each other by means of a deformable wall (14) of the matrix, which is adjusted to transform its space (16) smoothly under air exposure from a first configuration, wherein the cavity (15) comprises capsules of an adhesive (Z) applied in between, into a second configuration, wherein the wall (14) deformed elastically encloses the capsules at least partially to squeeze these capsules between the deformable wall and a cavity bottom to align and press them to each other. The group of inventions also refers to an assembly for capsule connection by the adhesive joint, comprising the above device.EFFECT: group of inventions provides damaging the capsules while fastening them by adhesion and ensured higher performance of the assembly for the adhesive joint of capsules.15 cl, 6 dwg
eans for treating intestinal infections and conditions induced by dysbacteriosis // 2572225
FIELD: medicine.SUBSTANCE: invention is presented in the form of a tablet and contains Bifidobacterium bifidum strain No1, lyophilised in a culture medium with activity 1×104-1×1010 CFU/g, calcium stearate, talc, sunchoke and lactose, with the components in the medium being in a specified ratio in wt %.EFFECT: extension of the arsenal of means, improving the condition of patients with intestinal dysbacteriosis.2 cl, 3 ex

Pharmaceutical composition possessing properties of vitamin d receptor activation // 2571503
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmaceutics, namely to a pharmaceutical composition possessing a property of vitamin D receptor (VDR) activation. The oral pharmaceutical composition contains paricalcitol as an active component, and a polar carrier representing sodium caseinate or fatty acid mono- and/or diglycerides; the paricalcitol content is from 0.0005 to 0.012 wt %.EFFECT: composition possesses high stability and preserved high clinical effectiveness that is ensured by using the polar carrier representing fatty acid mono- and/or diglycerides or sodium caseinate.5 cl, 3 tbl, 16 ex

Solid drug form of medication with sedative and antispasmodic effect // 2570374
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to the field of medicine, in particular to medications, containing organic active ingredients, namely to medications, demonstrating a sedative and soporific effect, and can be used for the treatment of somatoform dysfunction of the vegetative nervous system, neuroses with an increased irritability, increased excitation, insomnia, neurocirculatory dystonia, early stage of hypertensive disease, mildly expressed spasm of the cardiac vessels, spasm of the digestive tract organs, associated with neurovegetative disorders. A solid drug form of the medication with the sedative and soporific effect in the form of tablets or hard capsules contains ethyl ether of α-bromoisovaleric acid and mint oil or its mixture with hop oil, β-cyclodextrin, doxylamine, guaifenesin and auxiliary substances, including structured water.EFFECT: effective solid drug form of the preparation was created by increasing the sedative efficiency of Korvaltab tablets.5 cl, 8 tbl, 8 ex

Enteric-coated soft capsule and method for producing it // 2569742
FIELD: medicine.SUBSTANCE: capsules are filled with oily solutions of fat-soluble vitamins, and/or oil extracts from herbal and/or animal raw material, and/or fatty oils, and/or mixes thereof. The group of inventions also concerns a method for producing a solution used to prepare a coating of the above capsule, a method for producing the above capsule and a method for hardening the capsule coating.EFFECT: enteric capsules with a swelling agar coating having the rheological and structural-mechanical properties as good as those of a gelatine coating, more resistant to humidity variations, making it possible to add water-soluble biologically active substances and produce agar capsules with the use of encapsulation equipment for soft gelatine capsules.17 cl, 27 ex, 2 dwg

Preparation with liposomes, containing succinic acid and propolis extract, possessing disintoxication and antioxidant activity // 2561591
FIELD: pharmacology.SUBSTANCE: capsules for per oral introduction contain liposomes, obtained at mixing of egg lecithin and cholesterol. Liposomes contain succinic acid and 10% alcohol extract of propolis as active substances, saccharose and water purified with the following component ratio, a g per 1 capsule: succinic acid - 0.1; alcohol propolis extract 10% - 0.2; 0.2% saccharose water solution - 0.02, suspension of phosphatidylcholine and cholesterol in ratio 1:0.2 - 0.3, as auxiliary substances.EFFECT: preparation has disintoxicating and antioxidant, as well as antiedematous, spasmolytic, anti-inflammatory, regenerating and antibacterial action, uniform release of active substances and expressed prolonged action, is convenient for independent application by patients.3 cl, 5 tbl, 6 ex

Pharmaceutical compositions for treating cerebrovascular disorders and methods for preparing them // 2559776
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to medicine, particularly to pharmacology and pharmacy, and concerns a pharmaceutical composition for treating cerebrovascular disorders characterised by the fact that it contains an active substance 1-oxy-4-adamantanone and pharmaceutically acceptable target additives applicable in solid dosage forms specified in additive substances of the following groups: loosening, binding, hardening, anti-adhering and stripping off from the matrix, film coatings in certain proportions. The composition is presented in the form of tablets, capsules and contains an optimum amount of the additives.EFFECT: dosage forms based on the given pharmaceutical composition comply with the requirements of State Pharmacopoeia, Issue XII.17 cl, 1 dwg, 2 tbl, 9 ex

Tabletted pharmaceutical composition for treating severe forms of viral infections // 2559179
FIELD: medicine.SUBSTANCE: invention represents a tabletted pharmaceutical composition for treating severe forms of viral infections characterised by the fact that as therapeutic agents it contains interferon specified in a group of: recombinant interferon alpha, recombinant interferon beta, recombinant interferon gamma, antioxidants specified in a group of: mexidol, emoxypine, dibunol, alpha-lipoic acid, carnitine chloride; amino acid specified in a group of: acetyl cysteine, cysteine, lysine, arginine; anabolic regenerants specified in a group of: potassium orotate, riboxine, methyluracyl, as well as a form-building base with the ingredients in the composition taken in certain relation, g per 1 g of the mixture.EFFECT: extending the range of products for treating severe forms of viral infections, high bioavailability and reducing length of treatment.5 cl, 1 tbl, 4 ex

icrodispersed histo-equivalent bioplastic material // 2557529
FIELD: medicine.SUBSTANCE: what is described is a microdispersed histo-equivalent bioplastic material containing hyaluronic acid, a buffer system, clarithromycin and a proton pump inhibitor. Hyaluronic acid is nanostructured, lyophilised and dispersed to powder with a single particle size falling within the range of 50-100 mcm; the buffer system is Buffer-G with pH 6.8-8.0, while the proton pump inhibitor is the inhibitor H+-K+-Adenosine triphosphatase pantoprazole in the following proportions, wt %: hyaluronic acid - 95, Buffer-G with pH 6.8-8.0- 3, pantoprazole -1, clarithromycin -1; the microdispersed histo-equivalent bioplastic material is placed into capsules melted on exposure to body temperature, e.g. gelatine.EFFECT: using it for the therapeutic treatment of gastroduodenal ulcers and erosions with the effect of accelerated oral tissue regeneration.1 tbl

icroparticles with antibiotic for inhalation // 2555772
FIELD: medicine.SUBSTANCE: claimed invention relates to capsule for application with inhalator of dry powder, which contains composition in form of dry powder for pulmonary introduction, which contains mechanosynthesised microparticles, consisting of antibiotic and magnesium stearate.EFFECT: invention relates to method of obtaining claimed capsule and its application in treatment of bacterial infection, associated with certain lungs diseases.10 cl, 4 ex, 3 tbl, 1 dwg
 
2550991.
Up!